Efficacy and safety of evolocumab in reducing lipids and cardiovascular events Sabatine MS, Giugliano RP, Wiviott SD, et al. N Engl J Med 2015; 372: 1500-1509 Inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) is a novel strategy for LDL cholesterol (LDL-C) reduction, which has delivered promising results in phase 3 trials. In particular, marked reductions in LDL-C, but also triglycerides and lipoprotein(a), have been noted, even in patients already treated with statins. However, hard outcome data are likely to be required for these agents to achieve widespread acceptance.
Inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) is a novel strategy for LDL cholesterol (LDL-C) reduction, which has delivered promising results in phase 3 trials. In particular, marked reductions in LDL-C, but also triglycerides and lipoprotein(a), have been noted, even in patients already treated with statins. However, hard outcome data are likely to be required for these agents to achieve widespread acceptance.
This report analysed combined data from open label trials of evolocumab, a monoclonal antibody against PCSK9, and identified a significant reduction in cardiovascular events in the treatment arm (hazard ratio 0.47 vs. control group, P ¼ 0.003) after 12 months of treatment. One point of potential concern was a higher incidence of neurocognitive adverse events (0.9% vs. 0.3%), although this was not related to extent of LDL-C reduction.
In summary, this (and another article from the same edition reporting similar results with a related agent) provides the first evidence that PCSK9 inhibition reduces cardiovascular events -a finding that has been expected but nevertheless required confirmation. Further cardiovascular events after ST-elevation myocardial infarction (STEMI) are common, even though outcomes have been substantially improved by early primary percutaneous coronary intervention (PPCI). This sub-study of the PLATO (PLATelet inhibition and patient Outcomes) trial included 5395 patients and evaluated three biomarkers (N-terminal pro-Btype natriuretic peptide [NT-proBNP] , GDF-15 [growth differentiation factor-15] and high-sensitivity cardiac troponin T) for the prediction of subsequent events in patients with STEMI treated with PPCI.
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Only NT-proBNP and GDF-15 showed prognostic value for spontaneous MI during one-year follow-up (both P < 0.0001), with a net reclassification index of 0.22 and 0.05, respectively, when added to baseline clinical characteristics and angiographic extent of coronary artery disease.
It was concluded that for incremental risk stratification in patients with STEMI treated with PPCI, NT-proBNP and GDF-15 would provide additional information to what is currently available to clinicians. 
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